What is MAGIC?
Minimally-invasive Reliable Glucose monitoring in Intensive Care (MAGIC) is an EIC Accelerator-backed project which essentially comprises GlucoSet’s remaining efforts to become market ready.
MAGIC goal: TRL8
The project’s goal is to take GlucoSet’s technology from TRL6 to TRL8, ie. ready to submit for regulatory approval.
Most important events to date:
Financial de-risking
The most immediate impact on GlucoSet is that the grant and the blended finance mechanism was critical in helping GlucoSet finalize the first closing of its Series A round in Q2 2023;
Technological de-risking
In Q2 2023, GlucoSet reached several technology milestones, which helped de-risk the project and increase likelihood of the project’s success.
For up-to-date news relating to MAGIC, follow GlucoSet on LinkedIn.
This project has received funding from the European Union’s Horizon Europe Research and Innovation program, under Grant Agreement nº 190140677. The content of this publication represents the view of the author only and is his/her sole responsibility: it cannot be considered to reflect the views of the European Commission. The European Commission does not accept responsibility for the use that may be made of the information it contains.